<DOC>
	<DOCNO>NCT02419742</DOCNO>
	<brief_summary>This prospective , phase IV , multi-center , single arm , open-label , interventional study patient Human Epidermal growth factor Receptor 2 ( HER2 ) -positive node positive High risk node negative breast cancer .</brief_summary>
	<brief_title>Safety Efficacy Trastuzumab Part Breast Cancer Treatment Regimen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm early invasive HER2 positive , node positive high risk node negative breast cancer evidence residual , locally recurrent metastatic disease define clinical stage I IIIA eligible adjuvant treatment Trastuzumab . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . HER2 overexpression/amplification define either IHC3+ , IHC2+ Fluorescence situ Hybridization ( FISH ) positive determined central laboratory . At time start Trastuzumab therapy , Left ventricular ejection fraction ( LVEF ) measure echocardiography . Screening leave ventricular ejection fraction ( LVEF ) =/ &gt; 55 % . Adequate bone marrow , renal , hepatic function . Agreement use adequate , nonhormonal mean contraception woman childbearing potential . Any contraindication Trastuzumab . Previous adjuvant breast cancer treatment approve investigational antiHER2 agent . History malignancy , except curatively treat carcinoma situ cervix basal cell carcinoma patient curatively treated malignancy diseasefree least 5 year . Past history ductal carcinoma situ and/or lobular carcinoma treat systemic therapy radiation therapy ipsilateral breast invasive cancer subsequently develop . Locally advanced ( stage IIIB IIIC ) Metastatic disease ( stage IV ) . Clinically relevant cardiovascular disorder disease . Uncontrolled hypertension , history hypertensive crisis hypertensive encephalopathy . History severe allergic immunological reaction , e.g . difficult control asthma . Pregnant lactating woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>